Key study into anti-stroke drug (Rivaroxaban) taken by millions found to be ‘unreliable’ and potentially fatal side effects were ignored, documents reveal
- Rivaroxaban is approved by NICE for the prevention of stroke and embolisms
- In 2009, a study on the blood thinner appeared to show it was safe and effective
- But now medical journal The Lancet has warned of ‘inaccuracies’ in the trial data
NB: often sold under the brand name Xarelto